# Retatrutide in women: what the studies included · PepVault

Source: https://pepvault.app/guides/retatrutide-in-women

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Retatrutide in women: what the studies included

Reviewed November 2026 16 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Retatrutide in women: the share of women and ages in each trial, why Lilly capped women, how much more weight women lost, and why pregnancy was excluded.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 16
- **Questions:** 7
- **Compounds:** 3

## The short answer

Women made up about half of retatrutide's trial participants: 48% in the phase 2 obesity trial and 48 to 63% in the phase 3 trials that report it, with women capped at about 70% by design. Where results were split by sex, women lost more: 20.3 kg on average in phase 2 against 16.0 kg for men. Pregnant and breastfeeding women were excluded.

Every number checked at its primary source · Nov 20, 2026 · [16 sources](https://pepvault.app/guides/retatrutide-in-women#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Randomized, placebo-controlled phase 1b, 2 and 3 trials in people, sponsored by Eli Lilly; the sex split comes from phase 2's subgroup analyses (a meeting report and a meta-analysis) and a TRIUMPH-1 meeting presentation. Retatrutide is investigational and not approved.

## How many women were in the retatrutide trials?

Seven trials of retatrutide in people have reported who they enrolled. Retatrutide is one peptide that acts on three hormone receptors (GIP, GLP-1 and glucagon), made by Eli Lilly and still investigational. Every trial below was randomized and placebo-controlled, and every one was open to both sexes[1](https://pepvault.app/guides/retatrutide-in-women#source-1) [4](https://pepvault.app/guides/retatrutide-in-women#source-4) [5](https://pepvault.app/guides/retatrutide-in-women#source-5) [7](https://pepvault.app/guides/retatrutide-in-women#source-7) [9](https://pepvault.app/guides/retatrutide-in-women#source-9) [10](https://pepvault.app/guides/retatrutide-in-women#source-10) [11](https://pepvault.app/guides/retatrutide-in-women#source-11).

| Trial | Who and how long | Women | Average age |
| --- | --- | --- | --- |
| Phase 1b, 2022[5](https://pepvault.app/guides/retatrutide-in-women#source-5) [6](https://pepvault.app/guides/retatrutide-in-women#source-6) | 72 adults with type 2 diabetes, 12 weeks | Only women who could not become pregnant | Ages 20 to 70 could join |
| Phase 2 obesity, 2023[1](https://pepvault.app/guides/retatrutide-in-women#source-1) [3](https://pepvault.app/guides/retatrutide-in-women#source-3) | 338 adults with obesity or overweight, 48 weeks | 163 (48.2%) | 48.2 years |
| Phase 2 type 2 diabetes, 2023[4](https://pepvault.app/guides/retatrutide-in-women#source-4) | 281 adults with type 2 diabetes, 36 weeks | 156 (56%) | 56.2 years |
| TRIUMPH-1, 2026[7](https://pepvault.app/guides/retatrutide-in-women#source-7) [10](https://pepvault.app/guides/retatrutide-in-women#source-10) | 2,339 adults with obesity, no diabetes, 80 weeks | Capped at about 70%; 435 (75.8%) in its knee-arthritis group | Not in the abstract; 56.1 years in the knee-arthritis group |
| TRIUMPH-2, 2026[9](https://pepvault.app/guides/retatrutide-in-women#source-9) | 1,152 adults with obesity and type 2 diabetes, 80 weeks | 554 (48%) | 55.1 years |
| TRIUMPH-4, 2026[10](https://pepvault.app/guides/retatrutide-in-women#source-10) | 445 adults with obesity and knee arthritis, 68 weeks | 282 (63.4%) | 55.2 years |
| TRANSCEND-T2D-1, 2026[11](https://pepvault.app/guides/retatrutide-in-women#source-11) | 537 adults with type 2 diabetes, 40 weeks | 296 (55%) | 48.8 years |

The caps are the surprise. Obesity trials usually fill up with women, so Lilly set the mix on purpose: phase 2 enrolled roughly equal shares of women and men by design[13](https://pepvault.app/guides/retatrutide-in-women#source-13), and the phase 3 TRIUMPH program caps women at about 70% to make sure enough men take part[8](https://pepvault.app/guides/retatrutide-in-women#source-8) [10](https://pepvault.app/guides/retatrutide-in-women#source-10). Sex was also one of the factors the TRIUMPH trials balanced when they assigned people to a dose, so every arm got a similar mix of women and men[8](https://pepvault.app/guides/retatrutide-in-women#source-8) [10](https://pepvault.app/guides/retatrutide-in-women#source-10).

TRIUMPH-1's overall share of women and its average age are in the full NEJM paper, which we could not open; the 75.8% and 56.1 years are its knee-arthritis group of 574 people, reported in the TRIUMPH-4 paper[10](https://pepvault.app/guides/retatrutide-in-women#source-10).

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault keeps your weight log and your dose log side by side, so your own curve sits next to the trial averages instead of being guessed from memory.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Do women lose more weight on retatrutide than men?

Yes, in every split published so far. The phase 2 obesity trial looked at weight change at 48 weeks in women and men separately, and the first phase 3 trial did the same at 80 weeks. The doses named are the trials' arms, not a dose for anyone.

| Result | Women | Men |
| --- | --- | --- |
| Phase 2, all retatrutide arms, 48 weeks: average loss[14](https://pepvault.app/guides/retatrutide-in-women#source-14) | 20.3 kg | 16.0 kg |
| Phase 2, best arm, 48 weeks[13](https://pepvault.app/guides/retatrutide-in-women#source-13) | 28.5% (8 mg) | 21.9% |
| TRIUMPH-1, best arm, 80 weeks (meeting report)[12](https://pepvault.app/guides/retatrutide-in-women#source-12) | Up to 30.8% | 23.2% |

In phase 2, women lost 4.2% more of their body weight than men once placebo was taken into account, a statistically significant gap (P = .019)[13](https://pepvault.app/guides/retatrutide-in-women#source-13). A meta-analysis that pulled the trial's numbers for the 129 women and 139 men on retatrutide found the gap in kilograms too: 4.2 kg more for women[14](https://pepvault.app/guides/retatrutide-in-women#source-14).

The first phase 3 trial points the same way. At the American Diabetes Association meeting in June 2026, the TRIUMPH-1 team presented weight loss at 80 weeks of up to 30.8% in women and 23.2% in men, and called it consistent with phase 2[12](https://pepvault.app/guides/retatrutide-in-women#source-12). That split comes from a news report of the talk, not the published paper; the paper's abstract gives no split by sex[7](https://pepvault.app/guides/retatrutide-in-women#source-7).

<!--promo-->

PepVault keeps your weight log and your dose log side by side, so your own curve sits next to the trial averages instead of being guessed from memory. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-retatrutide-in-women-inline&mt=8)

<!--/promo-->

## Why do women lose a bigger share of their weight?

The trials were not built to answer it: the sex results are subgroup analyses, a lead to test rather than a settled result. What the data rule out is the simplest idea, that a percentage of a smaller body is just bigger arithmetic: in phase 2 women also lost more in kilograms[14](https://pepvault.app/guides/retatrutide-in-women#source-14). Sex was the strongest of the subgroup factors in the phase 2 analysis presented at ObesityWeek 2023, ahead of starting weight and age[13](https://pepvault.app/guides/retatrutide-in-women#source-13).

The same pattern shows up across the whole drug class. A meta-analysis of 14 trials that reported weight by sex, covering dulaglutide, exenatide, liraglutide, semaglutide and retatrutide, found women lost more on average, and the gap widened as the weight loss got larger[14](https://pepvault.app/guides/retatrutide-in-women#source-14). A second network meta-analysis of 19 obesity trials found better results in trials with more women[15](https://pepvault.app/guides/retatrutide-in-women#source-15). Retatrutide, with the largest weight loss of the group, showed the largest gap[14](https://pepvault.app/guides/retatrutide-in-women#source-14).

One practical reading follows from the trial design. Because phase 2 enrolled about equal shares of women and men on purpose, the lead investigator said this may have dampened its overall results compared with trials that enrolled more women[13](https://pepvault.app/guides/retatrutide-in-women#source-13).

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)
- [Statistically significant](https://pepvault.app/glossary/statistical-significance)

## Does retatrutide work for women over 50?

Women in their 50s are well represented. The phase 3 trials that report an average age landed between 48.8 and 55.2 years[9](https://pepvault.app/guides/retatrutide-in-women#source-9) [10](https://pepvault.app/guides/retatrutide-in-women#source-10) [11](https://pepvault.app/guides/retatrutide-in-women#source-11). Phase 2 was open to adults aged 18 to 75, with an average age of 48.2[3](https://pepvault.app/guides/retatrutide-in-women#source-3), and about half its participants (167 of 338) were 50 or older[13](https://pepvault.app/guides/retatrutide-in-women#source-13).

In the phase 2 subgroup analysis, women aged 50 and older lost 8% more body weight than men of the same age, a statistically significant gap (P = .002); the report does not say whether that means percentage points[13](https://pepvault.app/guides/retatrutide-in-women#source-13). Younger adults lost more than older ones overall, so age and sex pull in different directions for an older woman[13](https://pepvault.app/guides/retatrutide-in-women#source-13).

None of the trials has published results split by menopause stage or by hormone therapy. Our guide to GLP-1s and menopause covers what the tirzepatide and semaglutide trials show there.

## Were pregnant or breastfeeding women in the retatrutide trials?

No. The trials kept pregnancy out by design, so there are no human data on retatrutide in pregnancy or breastfeeding.

- **Phase 1b:** women could join only if they could not become pregnant, after menopause or surgical sterilization[6](https://pepvault.app/guides/retatrutide-in-women#source-6).
- **Phase 2 obesity:** women who were pregnant, breastfeeding or planning a pregnancy were excluded, and women who could become pregnant needed adequate contraception[3](https://pepvault.app/guides/retatrutide-in-women#source-3).
- **Phase 3 TRIUMPH:** pregnancy is one of the reasons to stop the study drug[8](https://pepvault.app/guides/retatrutide-in-women#source-8).

Retatrutide's half-life is about 6 days[5](https://pepvault.app/guides/retatrutide-in-women#source-5), so it stays in the body for weeks after the last injection. The approved GLP-1s carry their own pregnancy guidance on their labels, covered in our guide to GLP-1s and pregnancy.

**When to get help** If you are pregnant, planning a pregnancy or breastfeeding, the trials give no answer for retatrutide, and the decision belongs with your doctor; a positive pregnancy test while taking any drug of this class is a reason to call them that week.

## Do side effects differ for women on retatrutide?

Little has been published by sex. The trials report side effects for everyone together, and in all of them the most common ones were stomach effects such as nausea and diarrhea[1](https://pepvault.app/guides/retatrutide-in-women#source-1) [7](https://pepvault.app/guides/retatrutide-in-women#source-7) [9](https://pepvault.app/guides/retatrutide-in-women#source-9), mostly mild to moderate in phase 2[1](https://pepvault.app/guides/retatrutide-in-women#source-1). The one sex-linked finding so far came from the TRIUMPH-1 presentation: urinary tract infections were more common on retatrutide (6.8 to 8.1%) than on placebo (4.8%), mostly mild to moderate and cleared with treatment, and 92% of them were in women[2](https://pepvault.app/guides/retatrutide-in-women#source-2) [12](https://pepvault.app/guides/retatrutide-in-women#source-12). Those figures come from the meeting; the published paper's table is the final word.

**Commonly reported:** appetite dropping in the first weeks, often described as stronger than on tirzepatide, and stomach effects after each step-up that settle within one to two weeks.

Our retatrutide side effects guide has the full rates by dose, and the safety guide covers what the trials found on the pancreas, the heart and the skin sensation called dysesthesia.

## What do the retatrutide trials not tell women yet?

- Anything about pregnancy or breastfeeding: both were excluded.
- Results by menopause stage or by hormone therapy.
- A published sex split from phase 3: TRIUMPH-1's came in a meeting talk, and TRIUMPH-2, TRIUMPH-4 and TRANSCEND-T2D-1 give none in their abstracts or, for TRIUMPH-4, its main text[9](https://pepvault.app/guides/retatrutide-in-women#source-9) [10](https://pepvault.app/guides/retatrutide-in-women#source-10) [11](https://pepvault.app/guides/retatrutide-in-women#source-11) [12](https://pepvault.app/guides/retatrutide-in-women#source-12).
- Whether women lose more against tirzepatide too: TRIUMPH-5, the head-to-head trial, has not reported[16](https://pepvault.app/guides/retatrutide-in-women#source-16).

Retatrutide is still investigational[10](https://pepvault.app/guides/retatrutide-in-women#source-10), so no regulator has issued a label with a women's section yet. When the TRIUMPH-1 paper's sex tables are public, this guide gets a new review date.

<!--promo-->

PepVault logs each dose with its date and sends a reminder on dose day, so the record you bring to your doctor is complete. [Set reminders in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-retatrutide-in-women-inline&mt=8)

<!--/promo-->

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. [PubMed 37366315](https://pubmed.ncbi.nlm.nih.gov/37366315/)
2. Eli Lilly. The first phase 3 obesity study of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with obesity (TRIUMPH-1). ADA 86th Scientific Sessions, 2026 (Lilly HCP congress page). [lilly.com](https://lilly.com/hcp/congresses/ada-2026/dv039292-triumph-1)
3. ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or are overweight (phase 2; sponsor Eli Lilly and Company). Record and results. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04881760)
4. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. [PubMed 37385280](https://pubmed.ncbi.nlm.nih.gov/37385280/)
5. Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022. [PubMed 36354040](https://pubmed.ncbi.nlm.nih.gov/36354040/)
6. ClinicalTrials.gov NCT04143802. A study of LY3437943 in participants with type 2 diabetes mellitus (phase 1b; sponsor Eli Lilly and Company). Eligibility criteria. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04143802)
7. Jastreboff AM et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med. 2026. [PubMed 42814954](https://pubmed.ncbi.nlm.nih.gov/42814954/)
8. Giblin K et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026. [PubMed 41090431](https://pubmed.ncbi.nlm.nih.gov/41090431/)
9. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. [PubMed 42810372](https://pubmed.ncbi.nlm.nih.gov/42810372/)
10. Schnitzer TJ et al. Retatrutide once weekly in adults with knee osteoarthritis pain and obesity (TRIUMPH-4 and TRIUMPH-1-OA). N Engl J Med. 2026. Author accepted manuscript (Table 1), White Rose Research Online. [PubMed 43001755](https://eprints.whiterose.ac.uk/id/eprint/247091/1/NEJMoa2610676-manuscript.pdf)
11. Bajaj HS et al. Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. [PubMed 42250575](https://pubmed.ncbi.nlm.nih.gov/42250575/)
12. Evangelou C. Retatrutide reduces body weight by nearly 30% in phase 3 TRIUMPH-1 trial, with gains for sleep apnea and knee pain. Doximity Op-Med, June 16, 2026 (news report of the ADA 86th Scientific Sessions presentation). [opmed.doximity.com](https://opmed.doximity.com/articles/retatrutide-reduces-body-weight-by-nearly-30-in-phase-3-triumph-1-trial-with-gains-for-sleep-apnea-and-knee-pain)
13. Monostra M. Weight loss varies with investigational triple agonist for adults with obesity. Healio, Endocrine Today (report of the ObesityWeek 2023 presentation). [healio.com](https://www.healio.com/news/endocrinology/20231213/weight-loss-varies-with-investigational-triple-agonist-for-adults-with-obesity)
14. Yang Y et al. Sex differences in the efficacy of glucagon-like peptide-1 receptor agonists for weight reduction: a systematic review and meta-analysis. J Diabetes. 2025. [PubMed 40040445](https://pubmed.ncbi.nlm.nih.gov/40040445/)
15. Sinha B et al. Efficacy and safety of GLP-1 receptor agonists, dual agonists, and retatrutide for weight loss in adults with overweight or obesity: a Bayesian NMA. Obesity (Silver Spring). 2025. [PubMed 40685589](https://pubmed.ncbi.nlm.nih.gov/40685589/)
16. ClinicalTrials.gov NCT06662383. A study of retatrutide (LY3437943) compared to tirzepatide (LY3298176) in adults who have obesity (TRIUMPH-5; sponsor Eli Lilly and Company). Active, not recruiting; no results posted. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06662383)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)

Which peptides were tested in women: semaglutide, tirzepatide, PT-141, GHK-Cu, collagen, BPC-157, tesamorelin and HGH, with how many women and what was found.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Retatrutide Studied range: 1–12 mg](https://pepvault.app/peptides/retatrutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)
- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)

## Related guides

- Guide · GLP-1s

  ### [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)

  Retatrutide side effects by dose in its trials: nausea, diarrhoea, skin tingling and heart rate, when they show up, how many stopped, and what helps.

  Read the guide
- Guide · GLP-1s

  ### [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)

  Is retatrutide safe? What its trials counted of pancreatitis, gallbladder and heart events, low blood sugar and deaths, who was left out, and what is unknown.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)

  Retatrutide dosage in trials: a 2 mg weekly start, a step up every four weeks to 4, 9 or 12 mg in phase 3, what phase 2 tested, and why no label exists.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)

  What to expect on retatrutide week by week: the trial dose steps, when appetite drops, weight loss at weeks 24, 48 and 80, and how side effects settle.

  Read the guide
- Guide · GLP-1s

  ### [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)

  TRIUMPH-5 puts retatrutide against tirzepatide in about 800 adults. What it tests, the numbers to beat, when it should report and how to read the result.

  Read the guide
- Guide · GLP-1s

  ### [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)

  GLP-1s in menopause: tirzepatide weight loss by menopause stage, semaglutide with hormone therapy, the pill, bone and fractures, and the hot-flash trials.

  Read the guide
- Guide · GLP-1s

  ### [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)

  Ozempic, Wegovy, Mounjaro and Zepbound in pregnancy: each label's stop-before line, the pill warning, breastfeeding, wash-out times and what 2026 studies found.

  Read the guide
- Guide · The science

  ### [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)

  Which peptides were tested in women: semaglutide, tirzepatide, PT-141, GHK-Cu, collagen, BPC-157, tesamorelin and HGH, with how many women and what was found.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)
- [Statistically significant](https://pepvault.app/glossary/statistical-significance)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
